TV 목록 보기
주식상담
지난 주요뉴스 한국경제TV에서 선정한 지난 주요뉴스 뉴스썸 한국경제TV 웹사이트에서 접속자들이 많이 본 뉴스 한국경제TV 기사만 onoff
[PRNewswire] Switching to Ozempic(R) from another GLP-1 RA significantly 2020-06-14 20:40:28
further oral antidiabetic drug(s) or insulin.1 (BAGSVÆRD, Denmark, June 13, 2020 PRNewswire=연합뉴스) Novo Nordisk today announced results from two real-world studies: EXPERT, which confirms the efficacy Ozempic(R) (once-weekly semaglutide) demonstrated in the SUSTAIN clinical trial programme, and...
[PRNewswire] Oral semaglutide improves glycaemic control in people with type 2019-09-17 23:00:12
to those seen with subcutaneous semaglutide. "This analysis reinforces the findings seen throughout the PIONEER trial programme, demonstrating oral semaglutide's efficacy in HbA1c reductions compared to commonly used type 2 diabetes treatments," said Mads Krogsgaard Thomsen, executive vice...
[ 분야별 송고기사 LIST ]-외신 2019-06-12 15:00:08
본 美 영화광…기네스 기록 경신 190612-0231 외신-005309:32 [PRNewswire] Oral semaglutide demonstrated cardiovascular safety in people 190612-0238 외신-005409:37 인니 동물원 '깡마른 곰' 영상 퍼져…"관리 부실했나" 190612-0241 외신-005509:38 WSJ "실리콘밸리 동력원이었던 중국 자본, 이제는 독(毒)"...
[PRNewswire] Oral semaglutide demonstrated cardiovascular safety in people 2019-06-12 09:32:03
of cardiovascular death [15 (0.9%) events with oral semaglutide vs 30 (1.9%) events with placebo, HR 0.49, p=0.03] and non-fatal strokes [12 (0.8%) events with oral semaglutide vs 16 (1.0%) events with placebo, HR 0.74, non-significant]. The number of non-fatal myocardial infarctions with oral...
[ 분야별 송고기사 LIST ]-외신 2019-06-09 15:00:07
오점" 190609-0248 외신-003211:00 [PRNewswire] Oral semaglutide showed superior reductions in blood sugar vs 190609-0256 외신-003311:11 전문가들 "中 희토류 수출제한, 단기충격 있지만 대안 있다" 190609-0264 외신-003411:16 필리핀 '마약과 전쟁' 조사촉구 유엔인권전문가에 "자주권 침해" 190609-0267...
[PRNewswire] Oral semaglutide showed superior reductions in blood sugar vs 2019-06-09 11:00:49
body weight with oral semaglutide was similar to empagliflozin with no statistical differences at both 26 and 52 weeks (3.8 kg for oral semaglutide at both 26 and 52 weeks, 3.7 kg and 3.6 kg for empagliflozin, respectively). In PIONEER 4, for the primary endpoint at 26 weeks, oral semaglutide 14 mg...
[ 분야별 송고기사 LIST ]-외신 2019-03-24 15:00:08
우승…"금기 깼다" 190324-0303 외신-004313:15 [PRNewswire] Oral semaglutide 7 mg and 14 mg doses showed superior reductions 190324-0308 외신-004413:31 "中 극동지역 투자 확대에 러시아 '움찔'…반감 증폭" 190324-0318 외신-004514:01 작년 對 인도 한국 투자 역대 최대…10억 달러 첫 돌파 190324-0319...
[PRNewswire] Oral semaglutide 7 mg and 14 mg doses showed superior reductions 2019-03-24 13:15:08
[PRNewswire] Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO (NEW ORLEANS, March 24, 2019 PRNewswire=연합뉴스) Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight...
[ 분야별 송고기사 LIST ]-외신 2018-06-24 08:00:05
외신-001305:26 [PRNewswire] Significant Blood Sugar Improvement With Xultophy(R) Compared to 180624-0058 외신-001405:27 [PRNewswire] Oral Semaglutide Demonstrated Significant Reduction in Blood 180624-0059 외신-001505:27 [PRNewswire] Ozempic(R) Provided Greater Weight Reductions for Adults With a...
[PRNewswire] Oral Semaglutide Demonstrated Significant Reduction in Blood 2018-06-24 05:27:08
oral semaglutide achieved significant HbA1c reductions compared to placebo (p<0.001 for all estimated treatment differences in HbA1c for oral semaglutide vs placebo). Furthermore, people treated with 14 mg oral semaglutide achieved significant reductions (p<0.001) in weight vs placebo while weight...
TV 목록 보기
주식상담
